Meridian Bioscience Inc.

NASDAQ:VIVO  
19.64
-0.12 (-0.61%)
Other Pre-Announcement

Meridian Bioscience Reports Q4 Adjusted EPS Of $0.23

Published: 11/12/2021 12:47 GMT
Meridian Bioscience Inc. (VIVO) - Meridian Bioscience Reports Strong Fourth Quarter and Record Full-year Fiscal 2021 Operating Results and Provides Fiscal 2022 Guidance.
Q4 Revenue Rose 19 Percent to $76.2 Million.
Q4 Adjusted Earnings per Share $0.23.
Q4 GAAP Earnings per Share $0.15.
Sees 2022 Consolidated Net Revenue $285 Million to $300 Million.
Sees 2022 Adjusted EPS $0.98 to $1.08.